MDDM's story of a breakthrough cancer treatment was confirmed by analyst, Frank Butterworth in his latest report.
I have attached the first page of that report for your review.
In addition, analysts HL Montgomery will be publishing their independent report within 10 days which will be distributed to no fewer than 10,000 investors and brokers.
There are many developments coming in the near future and I will do my
best to keep you informed.
Best regards,
Brian Bisset, Director of Corporate Communications
****************************************************************************
Mr. Butterworth was not compensated for this report, his sole interest
being the benefit of his paid subscribers.
Reprinted by Permission from Butterworth's Stock Pics.
****************************************************************************
Butterworth's Stock Pics Newsletter - April 1999
"MDM Group Inc. will become one of Wall Street's legends."
Future Giant
One Huge Step for Mankind!
Where will we find the next Pfizer, Amgen or Abbott Labs?
In my opinion. MDM Group Inc. will become one of Wall Street's legends.
Great News! Breakthrough Cancer Treatment
MDM Group Inc. (OTCBB:MDDM) - Price $14.00, 52 week stock price
high/low, $21/$2. MDDM has 10.1M shares outstanding, 800,000 warrants andhas a public float of less than one million shares.
This story is really "hot".
Dr. Richard Urban is the founder, President and Chief Executive Officer of Inter-Med Sciences, LLC and the developer of the NPP5 and NPP5A cancer treatment products. Dr. Urban's cancer treatment drug, (NPP5) has been successfully tested on human patients with an astounding 41% positive response rate on a broad range of cancers. Dr. Urban has further improved drug, NPP5 to make it more economical to produce and the treatment is now fully developed and no more research and development needs to be done. They hope to be in production within 45 days and for the remaining two to three
years they will be testing this drug. They will sell it outside of the North American Continent sometime in the year 2000.
MDM Group Inc. announced on 2/22/99 the entering into of preliminary agreements with its investment banker. Select Corporate Services, Inc., and S&S Biophysics Laboratory Pty. Ltd. (Laboratory). These agreements provide MDDM to have joint world commercialization rights to the Dielectric Diagnostic Analyzer, (DDA), a brand new product developed by the Laboratory. The DDA is a machine that is a major new technological breakthrough in the early detection of viral diseases, including cancer. DDA is the only instrument of its kind in the world. DDA will provide early stages of induction, before its clinical appearance. At present, in the world of medical technology, no such method exists. Subject to finishing the due diligence, MDDM will bring it online 2 to 3 years from now. In the near future, you will he able to be checked on your annual visit and know that
everything is all right, or if they need to start a program to treat any deadly cancers before they become a serious problem... caught early, before there are lumps or tumors. This is truly good news and in my opinion, an early opportunity to own a piece of what could be one of the worlds foremost suppliers of cancer treatment.
For more information please write:
MDM Group Inc.
mddm.net
101 East Park Blvd, Suite 711
Plano, TX. 75074
or call Investor Relations, 1-888-823-5767
Frank Butterworth
5405 Fairhill Dr., Austin, TX. 78745
Phone/Fax 1-512-442/8873
Email - buttrpcs@swbell.net
**************************************************************************** |
